Evidence map›Paper›PMID 39810256›Full record

ArticleAlzheimer's research & therapy2025

Exome sequencing reveals a rare damaging variant in GRIN2C in familial late-onset Alzheimer's disease.

Elisa Rubino, Maria Italia, Elisa Giorgio, Silvia Boschi, Paola Dimartino, Tommaso Pippucci, Fausto Roveta, Clara Maria Cambria, Gabriella Elia, Andrea Marcinnò and 6 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elisa Rubino *Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy. elisa.rubino@unito.it.
Maria Italia *Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, Milan, 20133, Italy.
Elisa Giorgio *Department of Molecular Medicine, University of Pavia, Via Forlanini 6, Pavia, 27100, Italy.
Silvia BoschiDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.
Paola DimartinoDepartment of Molecular Medicine, University of Pavia, Via Forlanini 6, Pavia, 27100, Italy.
Tommaso PippucciMedical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria, Via Albertoni 15, Bologna, 40138, Italy.
Fausto RovetaDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.
Clara Maria CambriaDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, Via Festa del Perdono 7, Milan, 20122, Italy.
Gabriella EliaDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.
Andrea MarcinnòDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.
Salvatore GalloneCenter for Alzheimer's Disease and Related Dementias, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, University Hospital, Via Cherasco 15, Turin, 10126, Italy.
Ekaterina RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, King's College Circle 1, Toronto, ON, M5S1A8, Canada.
Flavia AntonucciDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, Via Festa del Perdono 7, Milan, 20122, Italy.
Alfredo BruscoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.
Fabrizio Gardoni *Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, Milan, 20133, Italy.
Innocenzo Rainero *Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, Turin, 10126, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder with both genetic and environmental factors contributing to its pathogenesis. While early-onset AD has well-established genetic determinants, the genetic basis for late-onset AD remains less clear. This study investigates a large Italian family with late-onset autosomal dominant AD, identifying a novel rare missense variant in GRIN2C gene associated with the disease, and evaluates the functional impact of this variant.

methodsAffected and unaffected members from a Northern Italian family were included. Genomic DNA from family members was extracted and initially screened for pathogenic mutations in APP, PSEN1, and PSEN2, and screened for 77 genes associated with neurodegenerative conditions using NeuroX array assay. Exome sequencing was performed on three affected individuals and two healthy relatives. Bioinformatics analyses were conducted. Functional analysis was performed using primary neuronal cultures, and the impact of the variant was assessed through immunocytochemistry and electrophysiology.

resultsPathogenic variants were not identified in APP, PSEN1, or PSEN2, nor in the 77 genes in NeuroX array assay. Exome Sequencing revealed the c.3215C > T p.(A1072V) variant in GRIN2C gene (NM 000835.6), encoding for the glutamate ionotropic receptor N-methyl-D-aspartate receptor (NMDA) type subunit 2C (GluN2C). This variant segregated in 6 available AD patients in the family and was absent in 9 healthy relatives. Primary rat hippocampal neurons overexpressing GluN2C DISCUSSION: We identified a rare missense variant in GRIN2C associated with late-onset autosomal dominant Alzheimer's disease. These findings highlight the role of GluN2C-containing NMDARs in glutamatergic signaling and their potential contribution to AD pathogenesis.

Indexed as

Alzheimer DiseaseReceptors, N-Methyl-D-AspartateAgedAge of OnsetAnimalsExome SequencingFemaleHumansItalyMaleMiddle AgedMutation, MissenseNeuronsPedigreeRatsNR2C NMDA receptorReceptors, N-Methyl-D-Aspartate14-3-3Alzheimer’s diseaseGluN2CGRIN2CNMDAR

Identifiers

PMID39810256
PMCPMC11730494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.